Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5716228 | 1.00 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL10747717 | 1.00 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL5716232 | 1.00 | ACE (0.55) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9775310 | 0.98 | ACE (0.53) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL4404273 | 0.85 | ACE (0.53) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9256682 | 0.82 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL27605644 | 0.81 | ACE (0.39) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9592654 | 0.80 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL9773233 | 0.80 | CTSL (0.54) | ACEKMT2AMEN1USP2LMNA | |
| SCHEMBL8337646 | 0.79 | CHRM2 (0.45) | ACEKMT2AMEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288661-B2 | Process for the synthesis of (2S,3aS,7aS)-1-[(S)-alanyl]-octahydro-1H-indole-2-carboxylic acid compounds and application in the synthesis of perindopril | LES LABORATOIRES SERVIER (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20070123581-A1 | Process for the synthesis of (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid compounds and application in the synthesis of perindopril | LES LABORATOIRES SERVIER (FR) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123581-A1 | Process for the synthesis of (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid compounds and application in the synthesis of perindopril | CYP2S1, TPH1, AGTR1 | ACE 10/4885KMT2A 2054/4885MEN1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.